Zevra Therapeutics Overview
Zevra Therapeutics Target Price
Analysts' 12-month price predictions for ZVRA.
Get informed when a big investor buys or sells
+ FollowShare Price
$10.96
Average Target Price
$24.00
119% upside
119% upside2 analysts in the last 4 months
High: $25 | Low: $23
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-08 | GuggenheimEddie Hickman | $25 | 128.1% upside |  |
| 2026-03-10 | GuggenheimEddie Hickman | $23 | 109.9% upside | |
| 2025-12-30 | H.C. WainwrightBrandon Folkes | $26 | 137.2% upside | |
| 2025-11-06 | Cantor FitzgeraldKristen Kluska | $24 | 119% upside | |
| 2025-11-06 | Canaccord Genuity | $24 | 119% upside | |
| 2025-03-13 | Guggenheim | $22 | 100.7% upside | |
| 2025-03-12 | JMP Securities | $18 | 64.2% upside | |
| 2025-02-04 | GuggenheimZevra Therapeutics to $ | $21 | 91.6% upside | |
| 2024-09-24 | Roth CapitalJonathan Aschoff | $21 | 91.6% upside | |
| 2024-09-24 | Maxim GroupJason McCarthy | $25 | 128.1% upside | |
| 2024-09-24 | JMP SecuritiesJason Butler | $17 | 55.1% upside | |
| 2024-09-23 | H.C. WainwrightOren Livnat | $20 | 82.5% upside | |
| 2024-09-18 | Canaccord GenuitySumant Kulkarni | $22 | 100.7% upside | |